Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) Director Warren Whitehead sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of C$9.69, for a total value of C$48,450.00. Following the completion of the sale, the director now owns 58,000 shares of the company’s stock, valued at approximately C$562,020.
TSE APS traded down C$0.12 on Monday, reaching C$8.47. The stock had a trading volume of 61,352 shares, compared to its average volume of 97,126. The company has a debt-to-equity ratio of 1.63, a quick ratio of 20.33 and a current ratio of 20.56. Aptose Biosciences Inc. has a 12-month low of C$2.37 and a 12-month high of C$12.62. The business’s 50-day moving average price is C$10.06 and its 200 day moving average price is C$9.01. The stock has a market cap of $698.67 million and a P/E ratio of -16.07.
Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported C($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.14) by C($0.06). On average, sell-side analysts predict that Aptose Biosciences Inc. will post -0.65 earnings per share for the current year.
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: 52 Week Highs
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.